Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Ozempic Maker Novo Nordisk Is a Problem as Denmark's Economy Hits a Wall
06:12am, Friday, 29'th Aug 2025
The economy ministry blamed the slowdown on U.S. tariffs, but faltering demand for Ozempic and Wegovy could be another factor.
Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown
03:11am, Friday, 29'th Aug 2025
Denmark on Friday slashed its annual growth forecast to 1.4% from 3%. In this article NOVO.B-DK
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
05:15pm, Thursday, 28'th Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
04:41pm, Thursday, 28'th Aug 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2
LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights
10:13am, Thursday, 28'th Aug 2025
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. US Gastroenterologists and hepatologists highlight strong interest in Wegovy fo
Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO
08:45am, Thursday, 28'th Aug 2025
NEW YORK , Aug. 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class per
Novo Nordisk seeks new obesity, diabetes drugs with Replicate BioScience partnership
08:19am, Thursday, 28'th Aug 2025
Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held biot
2 Dividend Stocks to Hold for the Next 10 Years
04:29am, Thursday, 28'th Aug 2025
The healthcare industry is a good place to look for strong dividend-paying stocks. Many companies in the sector offer products that are consistently in demand, regardless of the state of the economy.
2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
03:26am, Thursday, 28'th Aug 2025
Investors looking for stocks that can outperform want to turn their attention to dividend payers, regardless of whether they're interested in building a passive income stream. Companies that pay divid
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
04:28pm, Wednesday, 27'th Aug 2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
02:50pm, Wednesday, 27'th Aug 2025
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025,
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Wednesday, 27'th Aug 2025
BENSALEM, Pa. , Aug. 27, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
11:55am, Wednesday, 27'th Aug 2025
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
